|
Marketing
The End of Pharma Marketing? Or a New Beginning?
FDA licensing approval is often touted as the essential marker of a new drug's success—but what counts far more is the skill of the developer in ensuring physicians, patients, and insurers prescribe it, pay for it, and use it. Making this connection is the function of the marketer. William Looney talks to two prominent commercial marketing experts on how this mission critical function must change to stay relevant ...Read more
Global
Medicine Pathways: Is Europe Trapped Again by Division?
MAPPs – medicine adaptive pathways to patients – is concerned with getting good new medicines to patients and modernizing regulatory systems to take account of advances in biology. Europe has generated much of the leading thinking on how the process might resolve the clash between new and old. But no sooner has MAPPs attained currency than the EU has come up with STAMP — a new expert group intended to assist the process but which may well suffocate it. Reflector reports
...Read more
Drug Shortages
Manufacturers Weigh Strategies to Prevent Drug Shortages
Drug shortages are declining, but they're still a serious concern for regulatory authorities, policy makers and biopharma manufacturers. Jill Wechsler looks at a recent report on an August 2014 Drug Shortages Summit that urges manufacturers to improve supply sourcing, and also calls on health plans and hospitals to pay more for quality products ...Read more
Leadership
Pharm Exec’s 2015 Emerging Pharma Leaders — Nominate Now!
Pharm Exec is looking for the fresh faces of pharma leadership, and we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague — or yourself. The deadline for this year’s entries is April 15
...Read more
Pricing
Are Global Markets Free-Riding on the US?
"Global free-riding" is frequently raised in discussions about drug prices and the cost of drug development. The global free-riding problem is the perception that the U.S. is subsidizing drugs for the rest of the world due to its high drug prices compared to other countries in the world, but this is a complicated case to make, and the issue goes far beyond just getting a free ride ...Read more
|
